Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 2:40 p.m. ET.

Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 90 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook, and YouTube.

Media Contact Will Zasadny Inizio Evoke Comms (619) 961-8848 will.zasadny@inizioevoke.com media@sprucebio.com

Investors Samir Gharib President and CFO Spruce Biosciences, Inc. investors@sprucebio.com

Grafico Azioni Spruce Biosciences (NASDAQ:SPRB)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Spruce Biosciences
Grafico Azioni Spruce Biosciences (NASDAQ:SPRB)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Spruce Biosciences